Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -90.17% is 53% below its 5-year average of -58.82%, near the low end of its 5-year range (-92.43%–-21.81%).
As of the fiscal period ended Tuesday, June 30, 2026. 12.26% below its 12-month average of -80.32%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -90.17%.
RETURN ON INVESTED CAPITAL (ROIC)
-90.17%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-80.32%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-72.66%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-58.82%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
-12.26%
CURRENT VS 3Y AVG
-24.09%
CURRENT VS 5Y AVG
-53.29%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-33.39%
median of 614 covered companies
CURRENT VS SECTOR MEDIAN
-170.08%
vs the sector median at left
Bolt Biotherapeutics, Inc.
Market Cap
$6.92M
Return on Invested Capital (ROIC)
-90.17%
TTM Avg
-80.32%
3Y Avg
-72.66%
5Y Avg
-58.82%
Market Cap
$7.13M
Return on Invested Capital (ROIC)
-219.15%
TTM Avg
-109.13%
3Y Avg
-72.14%
5Y Avg
-33.59%
Market Cap
$6.70M
Return on Invested Capital (ROIC)
-57.11%
TTM Avg
-311.64%
3Y Avg
-524.77%
5Y Avg
-524.77%
Market Cap
$6.67M
Return on Invested Capital (ROIC)
-107.99%
TTM Avg
-407.39%
3Y Avg
-445.97%
5Y Avg
-342.27%
Market Cap
$7.20M
Return on Invested Capital (ROIC)
-208.39%
TTM Avg
-54.78%
3Y Avg
-47.23%
5Y Avg
-47.23%
Market Cap
$7.20M
Return on Invested Capital (ROIC)
-102.91%
TTM Avg
-91.30%
3Y Avg
-374.81%
5Y Avg
-315.39%
Market Cap
$7.25M
Return on Invested Capital (ROIC)
N/A
TTM Avg
-383.35%
3Y Avg
-220.46%
5Y Avg
-246.83%
Market Cap
$7.27M
Return on Invested Capital (ROIC)
-232.05%
TTM Avg
-321.25%
3Y Avg
-211.94%
5Y Avg
-167.22%
Market Cap
$7.32M
Return on Invested Capital (ROIC)
-211.58%
TTM Avg
-206.45%
3Y Avg
-187.44%
5Y Avg
-143.49%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | $6.92M | -90.17% | -80.32% | -72.66% | -58.82% |
| Co-Diagnostics, Inc. (CODX)vs › | $7.13M | -219.15% | -109.13% | -72.14% | -33.59% |
| Aclarion, Inc. (ACON)vs › | $6.70M | -57.11% | -311.64% | -524.77% | -524.77% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.67M | -107.99% | -407.39% | -445.97% | -342.27% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.20M | -208.39% | -54.78% | -47.23% | -47.23% |
| Mangoceuticals, Inc. (MGRX)vs › | $7.20M | -102.91% | -91.30% | -374.81% | -315.39% |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.25M | N/A | -383.35% | -220.46% | -246.83% |
| KALA BIO, Inc. (KALA)vs › | $7.27M | -232.05% | -321.25% | -211.94% | -167.22% |
| Longeveron Inc. (LGVN)vs › | $7.32M | -211.58% | -206.45% | -187.44% | -143.49% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.33M | -995.44% | -481.38% | -268.85% | -219.77% |
ROIC
-90.2%
ROE
-227.4%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -90.17% |
| 2026-03-31 | -74.03% |
| 2025-12-31 | -71.68% |
| 2025-09-30 | -81.14% |
| 2025-06-30 | -84.57% |
| 2025-03-31 | -92.43% |
| 2024-12-31 | -85.71% |
| 2024-09-30 | -83.17% |
| 2024-06-30 | -71.05% |
| 2024-03-31 | -59.34% |
| 2023-12-31 | -54.69% |
| 2023-09-30 | -49.47% |
| 2023-06-30 | -47.17% |
| 2023-03-31 | -44.68% |
| 2022-12-31 | -44.13% |
| 2022-09-30 | -43.53% |
| 2022-06-30 | -40.37% |
| 2022-03-31 | -37.28% |
| 2021-12-31 | -32.12% |
| 2021-09-30 | -26.67% |
| 2021-06-30 | -21.81% |
| 2021-03-31 | -18.83% |
| 2020-12-31 | -139.41% |
| 2020-09-30 | -80.58% |
| 2020-06-30 | -61.10% |
| 2019-12-31 | -77.83% |
